FDA approves Vericel's MACI Arthro for arthroscopic knee cartilage repair

Vericel Corp

FDA approved sBLA for arthroscopic delivery of MACI (MACI Arthro) to repair knee defects up to 4 cm².
MACI Arthro targets largest segment of $3B addressable market: ~20,000 patients/year with 2-4 cm² femoral condyle defects.
Vericel expanding target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic cartilage repair surgeons.
MACI is first FDA-approved cellularized scaffold and first restorative biologic approved for arthroscopic administration.
CEO Nick Colangelo: approval supports sustained top-tier revenue growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.